In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Two Steps Back: Ligand Ditches Commercial Assets

Executive Summary

In early September, Ligand Pharmaceuticals announced it had unloaded its entire portfolio of marketed compounds, bringing in $518 million. The move goes against the grain of conventional wisdom in the biopharma world these days, where companies are still scrambling for clinical and commercial assets to forward integrate their businesses.
Advertisement

Related Content

Deal Watch: Auxilium Joins The Tax-Inversion Wave As BIO Keeps The Deal Tide High
Viking Explores Metabolic Disorders With Drugs Licensed From Ligand
Auctions: Getting the Best Value for Your Asset
Auctions: Getting the Best Value for Your Asset
The Approval Drought
The Approval Drought
ViroPharma's Second Act: First a Tough One to Follow
ViroPharma's Second Act: First a Tough One to Follow

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002841

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel